Table 13 Effects of CDK4/6 inhibitors or other therapeutic agents in clinical settings
From: A review on the role of cyclin dependent kinases in cancers
Tumor type | Samples | Inhibitors / Therapy | Function | References |
|---|---|---|---|---|
Breast cancer | 22 patients | CDK4/6 inhibitors | After 18 months CDK4/6 treatment, best objective response was complete response in 1, partial response in 8, and stable disease in 13 patients | [336] |
9771 patients | CDK4/6 inhibitors, PI3K inhibitor, and endocrine therapy | PFS was better in CDK4/6 inhibitors than PI3K inhibitors Combination of CDK4/6 inhibitors and endocrine therapy could increase OS than PI3K/mTOR inhibitors | [337] | |
3421 breast cancer patients | endocrine therapy and CDK4/6 inhibitors | In comparison with endocrine therapy alone, adding CDK4/6 inhibitors enhanced OS in patients with HR-positive, HER2-negative metastatic breast cancer But, adding of CDK4/6 inhibitors also increased the incidences of grade 3–4 adverse events | [338] | |
Breast cancer | 2968 patients | CDK4/6 inhibitors | Treatment with CDK4/6 inhibitors was found to be worse in patients with gBRCAm mBC than those with gBRCAwt and unknown gBRCA status | [339] |
71 patients | CDK4/6 inhibitors | A higher median value of Ki67 was observed in cases with second-line treatment, while the luminal B subtype was more prevalent. Luminal A subtype was correlated with a longer PFS. A higher continuous Ki67 value was correlated with shorter PFS. Luminal B subtype had a significantly worse outcome. PFS in patients with endocrine therapy in combination with CDK4/6i was inversely correlated with Ki67 expression but not with PR | [340] | |
43 patients, (17 prior CDK4/6i exposure) | CDK4/6 inhibitors, combination of EVE and EXE | No significant difference was found in PFS or OS between patients who had not received prior CDK4/6is and those who had | [341] | |
3182 patients | CDK4/6 inhibitors | CDK4/6 inhibitors could increase PFS in patients with HR-positive/ HER2-negative advanced breast cancer | [342] | |
ongoing phase II trial (NCT02308020) (pre-treated patients with CNS metastases) (including total 52 patients with HR + /HER2- CNS metastases are currently available) | CDK4/6 inhibitor (abemaciclib) | There was scarcity of data pertaining to the development of new CNS metastases | [343] | |
Breast cancer | 130 HR + BC patients and 83 endocrine‐resistant breast cancer patients | CDK4/6 inhibitors plus endocrine therapy | Patients receiving CDK4/6 inhibitors and endocrine therapy in the HMGB1‐positive group showed improved PFS in comparison with those in the HMGB1‐negative group | [215] |
30 patients | CDK4/6 inhibitors plus hormonal therapy | Patients had a PIK3CA mutation at the baseline of CDK4/6i treatment had a shorter PFS, in comparison with patients without mutation PIK3CA mutations were found to be predict response to CDK4/6i | [344] | |
2799 patients | CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) | Three inhibitors showed comparable efficacy, but they had differences in safety and tolerability. Abemaciclib showed worse tolerability with higher treatment discontinuation because of GI toxicity | [345] | |
160 patients (185 treatment occurrences) | PI3K/mTOR/CDK4/6 inhibitors | Inhibition of PI3K/mTOR/CDK4/6 could have an effect on the development of edema, so could cause or exacerbate progression of BCRL in patients with MBC | [346] |